Search the Newsreel

Good Neighbor Pharmacy® Named #1 in Customer Satisfaction with Chain Drug Store Pharmacies and Most Trusted by JD Power

Recognition coincides with ThoughtSpot, Cencora's flagship annual tradeshow and conference for community care providers CONSHOHOCKEN, Pa., July 29, 2026--(BUSINESS WIRE)--Good Neighbor Pharmacy, a national franchise for independent pharmacies offered through Cencora, has been ranked "#1 in Customer Satisfaction with Chain Drug Store Pharmacies" in …

AbCellera expands multispecific T-cell engager licensing with USD 28m Vertex deal for autoimmune disease

AbCellera Biologics has partnered with Vertex Pharmaceuticals in a deal worth $28 million upfront to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery while Vertex retains development and commercialization rights, with AbCellera eligible for milestone payments and royalties. …

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Wall Street expects a year-over-year increase in earnings on higher revenues when Cencora (COR) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

BABCOCK & WILCOX ENTERPRISES, INC. (NYSE: BW) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Babcock & Wilcox Enterprises, Inc. (“Babcock & Wilcox” or the …

AbCellera partners with Vertex on autoimmune therapies

AbCellera Biologics Inc. announced a collaboration with Vertex Pharmaceuticals Incorporated to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery and early development, receiving $28 million upfront plus potential milestone payments and royalties, while Vertex funds all R&D and retains commercialization rights. …

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

VANCOUVER, British Columbia, July 29, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. "We are excited to collaborate with Vertex, a recognized …

AbCellera Biologics, Inc. Revenue Breakdown – FWB:8QQ

AbCellera Biologics, Inc. (FWB:8QQ) generated €63.97 million last year, primarily from its Antibody Medicines segment. The company's highest revenue contribution geographically came from Canada, accounting for €54.49 million. This report provides a breakdown of the company's financial performance by segment and region for the …

AbCellera Biologics (ABCL) to Post Earnings on Wednesday

Abcellera Biologics Inc (ABCL) Income Statement

This article presents the quarterly and annual income statements for Abcellera Biologics Inc (ABCL), detailing revenues, operating expenses, and net income figures. It provides a comprehensive breakdown of financial performance over several fiscal periods, alongside frequently asked questions to help investors interpret the data. …

ABCL|Abcellera Biologics Inc|Price:5.310|Chg%:-0.360

This article provides a detailed company profile of Abcellera Biologics Inc (ABCL), an antibody discovery and development company. It outlines their business scope, financial data, and market performance, including an overview of their internal pipeline programs and key executive information. The report also lists …

Abcellera Biologics Inc (ABCL) Cash Flow

This article provides a detailed cash flow statement for Abcellera Biologics Inc (ABCL), presenting quarterly and annual data for operating, investing, and financing activities. It includes key metrics like operating cash flow, capital expenditures, and free cash flow, along with definitions and FAQs to …

AbCellera's AI-Driven Pivot: Why Jazz Pharma and ABCL635 Data Signal a New Era for the Biotech

AbCellera Biologics (ABCL) is transforming from an antibody discovery platform to a proprietary drug development company, evidenced by a significant collaboration with Jazz Pharmaceuticals worth up to $876 million and promising interim Phase 1 data for its lead internal program, ABCL635. This strategic pivot …

Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recent screening for stocks with rising P/E ratios and consistent price gains relative to the S&P 500 has put Cencora (COR) in focus for …

Abcellera Biologics, Inc. (ABCL) Q3 2023 Earnings Report - Results, Call & Slides

Abcellera Biologics (ABCL) reported its Q3 2023 earnings, beating EPS expectations but missing revenue targets. The company posted an actual EPS of -$0.10 against a consensus of -$0.12, representing a beat of +$0.02. However, actual revenue was $6.60M, significantly missing the expected $11.48M, and …

Cencora (COR) Stock Looks Undervalued As Its 167% Five Year Return Builds

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Cencora stock has delivered a strong 167.1% return over the past 5 years, yet its current valuation still screens as cheap. An intrinsic value estimate …

Babcock International Group PLC Revenue Breakdown – LSE:BAB

AbCellera Biologics Market Sentiment

This article provides an overview of AbCellera Biologics (ABCL) market sentiment based on analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target of $12, while short interest is rising at 20.6%. …

AbCellera Biologics, Inc. Revenue Breakdown – DUS:8QQ

AbCellera Biologics, Inc. (DUS:8QQ) generated €63.97 million in revenue last year, primarily from its Antibody Medicines segment. This represents a significant increase from €27.85 million in the previous year. The majority of the company's revenue, €54.49 million, originated from Canada.

Abcellera Biologics Inc (ABCL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's stock score system, which currently ranks its valuation score at 7.22 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -11.83, …

ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065

Abcellera Biologics Inc. (ABCL) is currently trading at $5.475, experiencing a -3.44% decrease. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate ABCL as a Buy, with …

Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides

Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.15 against a consensus of -€0.11 and actual revenue of €5.70M compared to an expected €6.73M. The Q3 2024 earnings call was scheduled …

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, aligning with its strategic focus on internal clinical programs and …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11

Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a significant potential market opportunity. This …

Babcock & Wilcox Enterprises (BW) Launches Buyback And Debt Redemption, Is It Still Undervalued?

Babcock & Wilcox Enterprises (BW) recently announced a share repurchase program of up to $50 million and the redemption of all $61.4 million of its 6.50% Senior Notes due 2026. Despite a recent sharp share price decline, the company still shows strong year-to-date and …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ: ABCL). The firm anticipates positive Phase 2 data for ABCL635, an anti-NK3R antibody for menopausal vasomotor symptoms, expecting favorable comparisons to approved inhibitors and a significant market opportunity. …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Babcock & Wilcox Enterprises, Inc. of Class Action Lawsuit - BW

Pomerantz LLP has issued an investor alert, reminding investors with losses in Babcock & Wilcox Enterprises, Inc. (NYSE: BW) of a class action lawsuit. The lawsuit targets investors who acquired securities between November 5, 2025, and March 11, 2026. Investors affected are encouraged to …

JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13

JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $13. This indicates continued confidence from the analyst firm in the company's stock performance.

Habco Trans (HATM) Akan Terbitkan 800 Juta Saham Baru Lewat Private Placement

Previsão ABCB4 — Preço Alvo para 2027

Banco ABC Brasil paga R$ 300,9 milhões em JCP e reforça atratividade de dividendos na B3

Banco brasileiro pagará "bolada" de R$ 1,17 por ação em JCP; descubra qual é

ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum

Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14

Lucro do Banco ABC (ABCB4) sobe apenas +2% no 1T26

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates